Raleigh, NC, United States
Raleigh, NC, United States

Patheon Inc. is a pharmaceutical company, incorporated in Canada with its corporate head offices in Durham, North Carolina, that provides contract development and manufacturing services of prescription and over-the-counter pharmaceutical products for approximately 300 pharmaceutical and biotechnology companies.Patheon's competitors in the contract manufacturing marketplace include Baxter and Cardinal Health, both based in the USA.In 2008, the company won the European Outsourcing Award in the category of Most Effective Scale-Up and Technical Transfer award. Wikipedia.


Time filter

Source Type

News Article | February 15, 2017
Site: cen.acs.org

Porton Fine Chemicals, a Chinese pharmaceutical ingredients producer, has agreed to acquire the South Plainfield, N.J.-based contract research firm J-Star Research. The move is the latest in a spate of acquisitions of independent U.S. chemistry research and manufacturing organizations by larger service firms. Formed in 1996, J-Star currently employs 47 people, most of them Ph.D. holders, the company says. Porton will pay up to $26 million for the firm, which is focused on early-phase clinical development of pharmaceutical chemicals. J-Star’s services encompass custom synthesis, process research, crystallization, and analytical services. J-Star CEO Andrew Thompson says the planned sale creates “a perfect match connecting our customized development capability with Porton’s advanced manufacturing experience.” Porton launched in 2005 to supply custom intermediate chemicals, mostly to large international drug firms such as Johnson & Johnson. Initially, Porton consisted of a manufacturing facility and a lab, both in Chongqing, southwest China. Its business grew rapidly. Porton listed on the Shenzhen stock exchange in 2014 and today claims 1,700 employees working at three sites in China. In 2013, the firm opened a facility in Chongqing producing active pharmaceutical ingredients to the U.S. Food & Drug Administration’s current Good Manufacturing Practices standards. And last month, it opened a process development center in Cranbury, N.J., about a 30-minute drive from South Plainfield. Porton’s deal for J-Star continues a trend of large pharmaceutical service firms acquiring independent U.S. providers of chemistry-related research and manufacturing services for the drug industry. In January, Pharmaron, a Beijing-based contract research firm, bought Xceleron, a U.S. supplier of mass spectroscopy technology. Last June, Universal Display purchased the Delaware contract research firm Adesis. In April 2016, India’s Piramal Enterprises bought Ash Stevens, a Michigan-based contract manufacturer. Also last year, Cambrex acquired North Carolina-based PharmaCore, and in 2015 Patheon purchased South Carolina’s Irix Pharmaceuticals.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Healthcare Contract Manufacturing Services Market Analysis: Service Types, Growth Trends, and Forecast to 2020, New Research by iHealthcareAnalyst, Inc. Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 Maryland Heights, MO, February 28, 2017 --( Browse Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 report at https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/ Pharmaceutical and medical devices contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) serves the pharmaceutical and medical device industry and provides clients with comprehensive services from drug or device development, through manufacture of pharmaceutical drugs, medical equipment or devices and parts. The pharmaceutical and medical device companies are outsourcing their drugs and devices manufacturing to concentrate on R&D and marketing of their products by minimizing the time invested in manufacturing practices. The global healthcare contract manufacturing services market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market based on service type (pharmaceutical manufacturing of API, FDF, drug formulations; and device manufacturing of medical equipment, materials, parts, electronic items), and forecasts growth trends (CAGR% - 2016 to 2020). The global healthcare contract manufacturing services market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global healthcare contract manufacturing services market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global healthcare contract manufacturing services market and included in this report are Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 28, 2017 --( PR.com )-- The global healthcare contract manufacturing services market to reach nearly USD 230 Billion in 2020, at a CAGR of 11.2% from 2016 to 2020, majorly due to lower cost of production. The market for contract manufacturing shows tremendous potential due to growth in the medical device industry, growing regulatory concerns and increasing demand from emerging countries.Browse Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 report at https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/Pharmaceutical and medical devices contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) serves the pharmaceutical and medical device industry and provides clients with comprehensive services from drug or device development, through manufacture of pharmaceutical drugs, medical equipment or devices and parts. The pharmaceutical and medical device companies are outsourcing their drugs and devices manufacturing to concentrate on R&D and marketing of their products by minimizing the time invested in manufacturing practices.The global healthcare contract manufacturing services market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market based on service type (pharmaceutical manufacturing of API, FDF, drug formulations; and device manufacturing of medical equipment, materials, parts, electronic items), and forecasts growth trends (CAGR% - 2016 to 2020). The global healthcare contract manufacturing services market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global healthcare contract manufacturing services market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global healthcare contract manufacturing services market and included in this report are Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations; and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 -- The global healthcare contract manufacturing services market to reach nearly USD 230 Billion in 2020, at a CAGR of 11.2% from 2016 to 2020, majorly due to lower cost of production. The market for contract manufacturing shows tremendous potential due to growth in the medical device industry, growing regulatory concerns and increasing demand from emerging countries.Pharmaceutical and medical devices contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) serves the pharmaceutical and medical device industry and provides clients with comprehensive services from drug or device development, through manufacture of pharmaceutical drugs, medical equipment or devices and parts. The pharmaceutical and medical device companies are outsourcing their drugs and devices manufacturing to concentrate on R&D and marketing of their products by minimizing the time invested in manufacturing practices.Browse Healthcare Contract Manufacturing Services Market by Service Types (Pharmaceutical Manufacturing of API, FDF, Drug Formulations;and Device Manufacturing of Medical Equipment, Materials, Parts, Electronic Items) 2016-2020 report at https://www.ihealthcareanalyst.com/ report/healthcare- cont... The global healthcare contract manufacturing services market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market based on service type (pharmaceutical manufacturing of API, FDF, drug formulations;and device manufacturing of medical equipment, materials, parts, electronic items), and forecasts growth trends (CAGR% - 2016 to 2020). The global healthcare contract manufacturing services market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global healthcare contract manufacturing services market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global healthcare contract manufacturing services market and included in this report are Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/healthcare-contract-manufacturing-services-market/


CARY, NC--(Marketwired - February 08, 2017) - The 2nd edition of Industry Standard Research's (ISR's) Drug Product Contract Manufacturer Quality Benchmarking report reveals that buyers of outsourced drug product manufacturing services value a strong regulatory history and reliable on-time delivery more than low cost when selecting a CMO for drug product manufacturing. The report includes information on respondents' outsourcing philosophies and practices, CMO perceptions and interactions and CMO selection drivers before diving into a series of in-depth performance analyses specific to the drug product offerings of 70 contract manufacturing organizations. 302 respondents provide rating assessments on 673 service encounters. "A strong regulatory track record topped the list of attributes as the most important factor influencing drug product CMO selection," said Kate Hammeke, Vice President, Market Research at Industry Standard Research. "Reliable on-time delivery placed second and a track record for meeting quality performance metrics came in third. Low cost had fewer than one-in-ten respondents mention it as the most important selection driver. We are hearing this more and more from service buyers. Cost is not necessarily becoming less important, but that multiple factors beyond project price impact overall costs and consequently those attributes outweigh 'low cost' as a selection criterion." The report provides a Consumer Reports-style analysis where each of the 70 CMOs included in the research is evaluated across 27 service quality attributes, making this report the most comprehensive assessment of quality in the contract manufacturing space. These performance metrics are categorized into four 'scorecards': Delivery Factors, Organization Factors, Capabilities and Staff Characteristics. From these performance evaluations, respondents indicated how well the manufacturers performed with respect to expectations specific to their experience working with the manufacturer(s). For buyers of outsourced services, the report includes highly valuable information to help guide CMO selection for drug product manufacturing projects. There are several stand-out CMOs this year: Pfizer CentreOne placed among the leaders across each of the four scorecards (Delivery, Organizational, Capabilities and Staff Characteristics) and Samsung BioLogics received top scores for its Organization Factors and Capabilities. Fareva received top marks for its Delivery Factors and among emerging market CMOs, Wuxi AppTec appeared among the leaders for its Organization Factors. CMO performance attributes evaluated by respondents include Full range of manufacturing for the dosage forms we require, Reliable on-time delivery, Regulatory History, Quality performance metrics, Scale-up and tech transfer abilities, Scientific knowledge, Right-first-time measurements, and many others. Data include an in-depth analysis of 20 of the 70 featured contract manufacturers, including AbbVie Contract Manufacturing, Albany Molecular Research Inc. (AMRI), Almac, Baxter BioPharma Solutions, Boehringer Ingelheim, Capsugel, Catalent, Dr. Reddy's CPS, Evonik, Fareva, GSK Contract Manufacturing, Patheon, PCI Pharma Services, Pfizer CentreOne, Piramal Pharma Solutions, Samsung BioLogics, Sandoz, Sanofi CEPiA, Vetter and Wuxi AppTec. For more information on ISR's "Drug Product Contract Manufacturer Quality Benchmarking" report, please visit ISR's report page at https://www.isrreports.com/reports/drug-product-contract-manufacturer-quality-benchmarking-2nd-edition/. Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR's off-the-shelf intelligence and custom research offerings, please visit the company's website at www.isrreports.com, email info@isrreports.com or follow ISR on Twitter @ISRreports.


News Article | February 15, 2017
Site: www.marketwired.com

CARY, NC--(Marketwired - February 09, 2017) - The 2nd edition of Industry Standard Research's (ISR's) Small Molecule API Contract Manufacturer Quality Benchmarking report reveals that the top performing CMOs relative to expectations, and based off customer feedback on recent service encounters, are contract manufacturers with a drug innovator as its parent company. "For the second year in a row, Pfizer CentreOne has been a top performer across all four scorecards," explained Kate Hammeke. "This year, AbbVie Contract Manufacturing placed among the leaders in three of the four scorecards. This is a sign that customers working with embedded CMOs are having their expectations exceeded, but so are respondents who outsource to small and midsize CMOs. Aesica, SAI Life Sciences and Wockhardt received top marks across two scorecards each, which is a sign that regardless of project size or company budget, one can find a CMO whose quality matches your organization's needs." The report includes information on buyers' outsourcing philosophies and practices, CMO perceptions and interactions, and CMO selection drivers before diving into a series of in-depth performance analyses specific to the small molecule offerings of 36 contract manufacturing organizations. 241 respondents provide rating assessments on 689 service encounters. The report provides a Consumer Reports-style analysis where each of the 36 CMOs included in the research is evaluated across 27 service quality attributes, making this report the most comprehensive assessment of quality in the contract manufacturing space. These performance metrics are categorized into four 'scorecards': Delivery Factors, Organization Factors, Capabilities and Staff Characteristics. From these performance evaluations, respondents indicated how well the manufacturers performed with respect to expectations specific to their experience working with the manufacturer(s). For buyers of outsourced services, the report includes highly valuable information to help guide CMO selection for small molecule projects from early clinical stages to commercialization. CMO performance attributes evaluated by respondents include Ability to manufacture small molecule API, Reliable on-time delivery, Regulatory history, Quality performance metrics, Scale-up and tech transfer abilities, Scientific knowledge, Right-first-time measurements, and many others. Data include an in-depth analysis of 27 of the 36 featured contract manufacturers, including AbbVie Contract Manufacturing, Aesica, Albany Molecular Research Inc. (AMRI), Alcami, Almac, AMPAC Fine Chemicals, Aptuit, Ash Stevens, Cambrex, Dr. Reddy's CPS, Evonik, GSK Contract Manufacturing, Halo Pharma, Lonza, Novasep, Patheon, Pfizer CentreOne, PharmaCore, Piramal Pharma Solutions, Recipharm, SAFC, SAI Life Sciences, Sanofi CEPiA, Siegfried, Wockhardt and Wuxi AppTec. For more information on ISR's "Small Molecule API Contract Manufacturer Quality Benchmarking" report, please visit ISR's report page at https://www.isrreports.com/reports/small-molecule-api-contract-manufacturer-quality-benchmarking-2nd-edition/ Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR's off-the-shelf intelligence and custom research offerings, please visit the company's website at www.isrreports.com, email info@isrreports.com or follow ISR on Twitter @ISRreports.


News Article | March 1, 2017
Site: www.prweb.com

The winners of awards for supply chain resilience and risk management excellence were honored by the Global Supply Chain Resiliency Council at its annual event which took place on Wednesday, March 1st, 2017, at the Embassy Suites by Hilton, in Milpitas, California. This year’s event attracted over 100 attendees from all over the country. There are over 1,200 general members of the Resiliency Council. The Resiliency Council was formed in 2015 by Resilinc founder and CEO, Bindiya Vakil along with supply chain luminaries from industry and academia. Its goal is to bring together supply chain risk management (SCRM) and resiliency practitioners with industry experts and thought leaders to advance the professional discipline through opportunities to collaborate, develop and share best practices, and be recognized for innovation and leadership. The awards program is one of the key elements of the Resiliency Council’s strategy to accelerate enterprise adoption of supply chain risk management and resiliency as a professional discipline and mission-critical business process. “As evidenced by the over 100% year-over-year growth in event participation/interaction and general membership, the Resiliency Council has emerged quickly as the leading SCRM professional community and think-tank,” said Bill Hurles, Executive Director. “We continue to believe that recognition of companies and individuals within that community will be critical to the institutionalization of resiliency concepts and business practices within the enterprise.” The awards program is designed to recognize organizations and individuals that serve as role models and leaders in driving supply chain resiliency strategy success within their company, supply chain network, and across industries. The awards committee considered nominations from its general membership of over 1,200 members worldwide comprised of OEMs/brand owners, suppliers, and experts from the Council’s technical advisor, Resilinc. The six company award categories and winners announced were as follows: General Motors For being an early adopter within your industry of advanced supply chain resiliency capabilities and technology, and for openly sharing your experiences and lessons learned with peers at public events and forums, thereby serving as a role model for others in the industry. Dave Leich, Director – Global Supply Chain, Paul Rossi, Supply Chain Risk Management Supervisor and James Preslar, Supply Chain Risk Analyst, accepted the award on behalf of General Motors. Boston Scientific For being an early adopter within your industry of advanced supply chain resiliency capabilities and technology, and for openly sharing your experiences and lessons learned with peers at public events and forums, thereby serving as a role model for others in the industry. Michael Landberg, Sourcing Manager, accepted the award on behalf of Boston Scientific Micron Technology For being an early adopter within your industry of advanced supply chain resiliency capabilities and technology, and for openly sharing your experiences and lessons learned with peers at public events and forums, thereby serving as a role model for others in the industry. Eric Knothe, Sr. Manager – Sourcing Compliance, accepted the award on behalf of Micron Technology. Patheon In recognition of the strong culture of partnering closely with customers on strategic initiatives, embracing technology and innovation, and for being a key contributor to your customers' success in achieving their vision for a resilient supply chain. John Upperman, Vice President - Procurement, Elvis Rodriguez, Purchasing Manager, accepted the award on behalf of Patheon. Dell/EMC In recognition of the organization's ability and willingness to embrace new technology, drive continuous innovation, and achieve mature state in technology-enabled processes for supply chain risk and resiliency management. Lisa Brady, Sr. Director – Sustainability & Risk Management and Dermot McDonald, Business Continuity Program Manager accepted the award on behalf of Dell/EMC. Thermo Fisher Scientific In recognition for effective collaboration with customers by building a transparent, trust-driven partnership, for your responsiveness and proactive support, and for embracing your customers' vision to achieve multi-enterprise supply chain resiliency. Lee Young, Director - Quality, and Rotimi Ogunbiyi, Supplier Quality Engineer, accepted the award on behalf of Thermo Fisher Scientific. About the Global Supply Chain Resiliency Council The Global Supply Chain Resiliency Council is a professional community and network for supply chain risk management practitioners, leaders, and stakeholders. The principal goals of the Council are to (1) bring together SCRM and resiliency practitioners with luminaries and thought leaders to advance the professional discipline through opportunities to collaborate, share best practices, and be recognized for innovation and leadership and (2) elevate the profile of supply chain risk management and resiliency challenges and opportunities vis-a-vis the C-level strategic agenda. The Global Supply Chain Resiliency Council has over 1,000 general members and has an open membership policy. Interested individuals within the business community and academia that wish to become a member of the community can do so by joining the LinkedIn discussion group by the same name.


Research and Markets has announced the addition of the "Global Empty Capsules Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Empty Capsules Market is poised to grow at a CAGR of around 8.6% over the next decade to reach approximately $2.9 billion by 2025. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. Some of the prominent trends that the market is witnessing include increasing demand for empty capsules in nutraceutical industry, increasing investments in research & development, and recent technological developments of empty capsules. Based on product type the market is categorized into non-gelatin capsules, gelatin capsules. Further, non-gelatin capsules are classified into pullulan and starch material, hydroxy propyl methy cellulose (hpmc). gelatin capsules are divided into bone meal, pig meat gelatin, bovine derived, and other gelatin capsules. On basis of therapeutic application the market is segmented by antianemic preparations (hematenic preparations), cough and cold preparations, anti-inflammatory drugs, antibiotic and antibacterial drugs, cardiovascular therapy drugs, vitamins and dietary supplements, antacid and antiflatulent preparations, and other therapeutic applications. Depending on the end user the market is segmented by research laboratories, pharmaceutical industry, cosmetics industry, and nutraceutical industry. - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments 3 Market Overview 3.1 Current Trends 3.1.1 Increasing demand for empty capsules in nutraceutical industry 3.1.2 Increasing investments in research & development 3.1.3 Recent technological developments of empty capsules 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 3.4.1 Bargaining power of suppliers 3.4.2 Bargaining power of buyers 3.4.3 Threat of substitutes 3.4.4 Threat of new entrants 3.4.5 Competitive rivalry 4 Empty Capsules Market, By Product 4.1 Non-Gelatin Capsules 4.1.1 Non-Gelatin Capsules Market Forecast to 2025 (US$ MN) 4.1.1.1 Pullulan and Starch Material 4.1.1.1.1 Pullulan and Starch Material Market Forecast to 2025 (US$ MN) 4.1.1.2 Hydroxy Propyl Methy Cellulose (HPMC) 4.1.1.2.1 Hydroxy Propyl Methy Cellulose (HPMC) Market Forecast to 2025 (US$ MN) 4.2 Gelatin Capsules 4.2.1 Gelatin Capsules Market Forecast to 2025 (US$ MN) 4.2.1.1 Bone Meal 4.2.1.1.1 Bone Meal Market Forecast to 2025 (US$ MN) 4.2.1.2 Pig Meat Gelatin 4.2.1.2.1 Pig Meat Gelatin Market Forecast to 2025 (US$ MN) 4.2.1.3 Bovine Derived 4.2.1.3.1 Bovine Derived Market Forecast to 2025 (US$ MN) 4.2.1.4 Other Gelatin Capsules 4.2.1.4.1 Other Gelatin Capsules Market Forecast to 2025 (US$ MN) 5 Empty Capsules Market, By Therapeutic Application 5.1 Antianemic Preparations (Hematenic Preparations) 5.1.1 Antianemic Preparations (Hematenic Preparations) Market Forecast to 2025 (US$ MN) 5.2 Cough and Cold Preparations 5.2.1 Cough and Cold Preparations Market Forecast to 2025 (US$ MN) 5.3 Anti-Inflammatory Drugs 5.3.1 Anti-Inflammatory Drugs Market Forecast to 2025 (US$ MN) 5.4 Antibiotic and Antibacterial Drugs 5.4.1 Antibiotic and Antibacterial Drugs Market Forecast to 2025 (US$ MN) 5.5 Cardiovascular Therapy Drugs 5.5.1 Cardiovascular Therapy Drugs Market Forecast to 2025 (US$ MN) 5.6 Vitamins and Dietary Supplements 5.6.1 Vitamins and Dietary Supplements Market Forecast to 2025 (US$ MN) 5.7 Antacid and Antiflatulent Preparations 5.7.1 Antacid and Antiflatulent Preparations Market Forecast to 2025 (US$ MN) 5.8 Other Therapeutic Applications 5.8.1 Other Therapeutic Applications Market Forecast to 2025 (US$ MN) 6 Empty Capsules Market, By End User 6.1 Research Laboratories 6.1.1 Research Laboratories Market Forecast to 2025 (US$ MN) 6.2 Pharmaceutical Industry 6.2.1 Pharmaceutical Industry Market Forecast to 2025 (US$ MN) 6.3 Cosmetics Industry 6.3.1 Cosmetics Industry Market Forecast to 2025 (US$ MN) 6.4 Nutraceutical Industry 6.4.1 Nutraceutical Industry Market Forecast to 2025 (US$ MN) - Acg Worldwide - Roxlor, LLC - JC biological technologies. - Suheung Co Ltd. - Qualicaps - Nectar Lifesciences Ltd - Capscanada Corporation - Sunil Healthcare Limited - Capsugel - Medi-Caps Ltd. - Patheon Ltd - Snail Pharma Industry Co., Ltd. - Bright Pharmacaps Inc. For more information about this report visit http://www.researchandmarkets.com/research/8thdmr/global_empty


News Article | March 1, 2017
Site: globenewswire.com

-- Phase 4 EXPAREL® study in total knee arthroplasty meets co-primary endpoints for pain control and opioid reduction against an active comparator -- -- EXPAREL net product sales up 11% year-over-year -- -- EXPAREL net product sales expected to be in the range of $290 to $310 million in 2017 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported financial results for 2016 and its outlook for 2017.  The company is also announcing positive topline results for its Phase 4 study of EXPAREL® in total knee arthroplasty, or TKA. “We made important progress in 2016 advancing our three-part EXPAREL growth strategy and setting the stage for continued success,” said Dave Stack, chief executive officer and chairman of Pacira. “We have multiple, major milestones on track for 2017, including the positive topline results reported today from our Phase 4 study in TKA. Our collaboration with DePuy Synthes is off to a strong start and will allow us to maximize these important data and broaden the use of EXPAREL as an opioid-sparing solution for prolonged postsurgical pain relief.” Pacira announces its full year 2017 financial guidance as follows. Pacira expects: See “Non-GAAP Financial Information” and “Reconciliations of GAAP to Non-GAAP 2017 Financial Guidance” below. The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Wednesday, March 1, 2017, at 8:30 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 40628335. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 40628335. The replay of the call will be available for two weeks from the date of the live call. The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call. This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP net income, non-GAAP cost of goods sold, non-GAAP gross margins, non-GAAP R&D and non-GAAP SG&A expenses, because such measures exclude stock-based compensation, amortization of debt discount, loss on extinguishment of debt, a termination fee with CrossLink BioScience, LLC and inventory and related reserves from the stability testing out of specification. These measures supplement our financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D and SG&A outlook for 2017 and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and the company’s future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP measures, and a reconciliation of our GAAP to non-GAAP 2017 financial guidance for gross margins, R&D and SG&A. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com. EXPAREL (bupivacaine liposome injectable suspension) is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com. EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for more details available at: http://www.exparel.com/hcp/pdf/EXPAREL_Prescribing_Information.pdf. Any statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL and our other products; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; our and Patheon UK Limited’s ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. * The convertible senior notes are contractually due in 2019. At December 31, 2016, the note holders did not have the ability to convert their notes at any time during the quarter ended March 31, 2017. However, because of certain conditions that were met during the three months ended December 31, 2015, the note holders could have converted their notes any time during the quarter ended March 31, 2016. (1) - In 2016, the Company recorded a $20.7 million charge to cost of goods sold to fully reserve $20.5 million for the cost of EXPAREL batches impacted by a routine stability test that did not meet required specifications and $0.2 million for replacement boxes and other related costs.


Patent
Patheon | Date: 2014-03-11

Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.


Patent
Patheon | Date: 2015-09-15

Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.

Loading Patheon collaborators
Loading Patheon collaborators